Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy

18 Mar 2021

Abstract excerpt

BACKGROUND: As neoadjuvant chemotherapy (NAC) is increasingly used in triple-negative breast cancer (TNBC), we investigated the value of circulating tumor DNA (ctDNA) for patient monitoring prior, during, and after NAC, and circulating tumor cells (CTCs) for disease characterization at clinical progression. MATERIALS AND METHODS: Forty-two TNBC patients undergoing NAC were prospectively enrolled. Primary tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33743331
DOI: 10.1016/j.esmoop.2021.100086

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapyPMID 33743331Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read ↗

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapySemantic proximity Read ↗

Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.Semantic proximity Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read ↗

Dynamic Analysis of Circulating Tumor DNA to Predict the Prognosis and Monitor the Treatment Response of Patients with Metastatic Triple-negative Breast Cancer: a prospective studySemantic proximity Read ↗

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer.Semantic proximity Read ↗

Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial resultsSemantic proximity Read ↗

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read ↗

Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.